Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (251-260 of 339) with videos related to

Pageof 34
Sort By:
The Lancet. Haematology|February 5, 2025
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort studyHege Kristin Gravdahl Garelius, Timothy Bagguley, Adele Taylor, et al.
Genes, Chromosomes & Cancer|September 25, 2018
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significanceJulie Schanz, Francesc Solé, Mar Mallo, et al.
Blood|July 8, 2016
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemiaChiara Elena, Anna Gallì, Esperanza Such, et al.
Nature Medicine|February 16, 2016
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9Rebekka K Schneider, Monica Schenone, Monica Ventura Ferreira, et al.
Nature Medicine|June 14, 2016
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicityRuth Eichner, Michael Heider, Vanesa Fernández-Sáiz, et al.
Annals of Hematology|May 21, 2017
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordanceLouise de Swart, Alex Smith, Marius MacKenzie, et al.
Annals of Hematology|June 15, 2017
Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantationMichael Heuser, Razif Gabdoulline, Patrick Löffeld, et al.
Leukemia Research|September 30, 2023
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromesTamanna Haque, Felix López Cadenas, Blanca Xicoy, et al.
Blood|September 28, 2013
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?Valeria Santini, Jennifer Schemenau, Alessandro Levis, et al.
Blood|August 28, 2013
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetLuca Malcovati, Eva Hellström-Lindberg, David Bowen, et al.
Pageof 34

Showing results (251-260 of 339) with videos related to

Sort By:
Pageof 34
The Lancet. Haematology|February 5, 2025
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort studyHege Kristin Gravdahl Garelius, Timothy Bagguley, Adele Taylor, et al.
Genes, Chromosomes & Cancer|September 25, 2018
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significanceJulie Schanz, Francesc Solé, Mar Mallo, et al.
Blood|July 8, 2016
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemiaChiara Elena, Anna Gallì, Esperanza Such, et al.
Nature Medicine|February 16, 2016
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9Rebekka K Schneider, Monica Schenone, Monica Ventura Ferreira, et al.
Nature Medicine|June 14, 2016
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicityRuth Eichner, Michael Heider, Vanesa Fernández-Sáiz, et al.
Annals of Hematology|May 21, 2017
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordanceLouise de Swart, Alex Smith, Marius MacKenzie, et al.
Annals of Hematology|June 15, 2017
Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantationMichael Heuser, Razif Gabdoulline, Patrick Löffeld, et al.
Leukemia Research|September 30, 2023
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromesTamanna Haque, Felix López Cadenas, Blanca Xicoy, et al.
Blood|September 28, 2013
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?Valeria Santini, Jennifer Schemenau, Alessandro Levis, et al.
Blood|August 28, 2013
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetLuca Malcovati, Eva Hellström-Lindberg, David Bowen, et al.
Pageof 34